Company news
Vaxcyte, Inc. (NASDAQ:PCVX) news
Every Vaxcyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 15, 2024
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 3, 2024
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 3, 2023
Vaxcyte Appoints Jacks Lee to Board of Directors
November 27, 2023
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 26, 2023
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 8, 2023
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
November 5, 2023
Vaxcyte to Present at Upcoming Investor Conferences
October 30, 2023
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
October 18, 2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
October 15, 2023
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 18, 2023
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
August 7, 2023
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
July 10, 2023
Vaxcyte to Present at the Jefferies Healthcare Conference
May 31, 2023
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
May 7, 2023
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
May 2, 2023
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 20, 2023
Vaxcyte Announces Pricing of $500 Million Public Offering
April 18, 2023
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
April 16, 2023
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
April 15, 2023
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
March 29, 2023
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 26, 2023
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
February 20, 2023
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 15, 2023
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
February 6, 2023
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
January 4, 2023
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
December 19, 2022
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
November 6, 2022
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 27, 2022
Vaxcyte Announces Pricing of $600 Million Public Offering
October 25, 2022
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
October 23, 2022
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
October 22, 2022
Vaxcyte Expands Executive Leadership Team with Key Appointments
October 10, 2022
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
September 5, 2022
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
August 7, 2022
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
August 3, 2022
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
July 11, 2022
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
June 26, 2022
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
May 8, 2022
Vaxcyte to Participate in Upcoming Investor Conferences in May
May 2, 2022
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
April 4, 2022
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
April 3, 2022
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 27, 2022
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
February 22, 2022
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 16, 2022
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Vaxcyte Announces Pricing of $100 Million Public Offering
January 12, 2022
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 11, 2022
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
January 5, 2022
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
November 9, 2021